Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.67 |
| ▸ | DDB1 | Q16531 | 12/20 | 0.65 |
| ▸ | IKZF3 | Q9UKT9 | 2/20 | 0.65 |
| ▸ | TNF | P01375 | 2/20 | 0.65 |
| ▸ | IL1B | P01584 | 1/20 | 0.65 |
| ▸ | TBXA2R | P21731 | 1/20 | 0.65 |
| ▸ | IKZF1 | Q13422 | 1/20 | 0.65 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.58 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.58 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.58 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.58 |
| ▸ | TSHR | P16473 | 1/20 | 0.58 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22737366 | 0.85 | CRBN (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL12041884 | 0.85 | CRBN (0.67) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24745183 | 0.85 | CRBN (0.65) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL30000850 | 0.82 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15440253 | 0.82 | CRBN (0.69) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24745645 | 0.82 | CRBN (0.59) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL31305237 | 0.82 | CRBN (0.66) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL15439785 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL24925477 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3TNFIL1B | |
| SCHEMBL20812206 | 0.81 | CRBN (0.61) | CRBNDDB1IKZF3TNFIL1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2877462-B1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2019-09-04 | — | — | EP | claimed |
| US-9133161-B2 | Processes for preparing isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2015-09-15 | — | — | US | claimed |
| EP-2877462-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | Celgene Corporation (US) | 2015-06-03 | — | — | EP | claimed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | claimed |
| WO-2014018866-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | WO | claimed |
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 THERAPEUTICS, INC. (US) | 2023-01-19 | — | — | US | disclosed |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2021-02-02 | — | — | US | disclosed |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | C4 THERAPEUTICS, INC. (US) | 2020-05-12 | — | — | US | disclosed |
| EP-2877462-B1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| EP-2877462-B1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORP (US) | 2019-09-04 | — | — | EP | disclosed |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | C4 Theraprutics, Inc. (US) | 2019-03-14 | — | — | US | disclosed |
| US-9133161-B2 | Processes for preparing isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| US-9133161-B2 | Processes for preparing isoindoline-1,3-dione compounds | CELGENE CORPORATION (US) | 2015-09-15 | — | — | US | disclosed |
| EP-2877462-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | Celgene Corporation (US) | 2015-06-03 | — | — | EP | disclosed |
| EP-2864325-A1 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | Janssen Sciences Ireland UC (IE) | 2015-04-29 | — | — | EP | disclosed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2014018866-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | WO | disclosed |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | CELGENE CORPORATION (US) | 2014-01-30 | — | — | US | disclosed |
| WO-2013186334-A1 | 1,3-DIHYDRO-2H-BENZIMIDAZOL-2-ONE DERIVATIVES SUBSTITUTED WITH BENZIMIDAZOLES AS RESPIRATORY SYNCYTIAL VIRUS ANTIVIRAL AGENTS | JANSSEN R&D IRELAND (IE) | 2013-12-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230014124-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885IKZF3 1040/4885 |
| US-10646575-B2 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885IKZF3 1040/4885 |
| US-10905768-B1 | Heterocyclic degronimers for target protein degradation | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885IKZF3 1040/4885 |
| US-20140031552-A1 | PROCESSES FOR PREPARING ISOINDOLINE-1,3-DIONE COMPOUNDS | UGT1A1, CYP3A5, CYP3A7 | CRBN 3545/4885DDB1 586/4885IKZF3 2093/4885 |
| US-20190076541-A1 | HETEROCYCLIC DEGRONIMERS FOR TARGET PROTEIN DEGRADATION | CRBN, MDM2, STUB1 | CRBN 1/4885DDB1 218/4885IKZF3 1040/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.